As of Mar 24
| +0.10 / +2.38%|
The 2 analysts offering 12-month price forecasts for Adamis Pharmaceuticals Corp have a median target of 7.50, with a high estimate of 10.00 and a low estimate of 5.00. The median estimate represents a +74.42% increase from the last price of 4.30.
The current consensus among 2 polled investment analysts is to Buy stock in Adamis Pharmaceuticals Corp. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.